SKP2 and small cell lung carcinoma: The other research team analyzed the genome-wide loss-of-function screening database to look for vulnerabilities in SCLC and they believed that S-phase kinase-associated protein 2 (SKP2) could be regarded as a new therapeutic target for SCLC, regardless of whether it is RB1 wild-type or mutant SCLC (42).